Sequential Icotinib Plus Chemotherapy
BD-IC-IV62
Approved small_molecule active
Quick answer
Sequential Icotinib Plus Chemotherapy for EGFR Positive Non-small Cell Lung Cancer is a Approved program (small_molecule) at Betta Pharmaceuticals Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Betta Pharmaceuticals Co.,
- Indication
- EGFR Positive Non-small Cell Lung Cancer
- Phase
- Approved
- Modality
- small_molecule
- Status
- active